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Abstract
An immune response can be activated by pathogenic stimuli, as well as endogenous danger 
signals, triggering the activation of pattern recognition receptors and initiating signalling cascades 
that lead to inflammation. This method uses THP1-Blue™ cells, a human monocytic cell line 
which contains an embryonic alkaline phosphatase reporter gene allowing the detection of NF-κB-
induced transcriptional activation. We validated this protocol by assessing NF-κB activation after 
stimulation of toll-like receptor 4 (TLR4) by two different agonists: lipopolysaccharide (LPS), 
derived from the cell wall of Gram negative bacteria, and tenascin-C, an extracellular matrix 
protein whose expression is induced upon tissue injury. We then used this protocol to screen for 
potential new endogenous TLR4 agonists, but this method can also be used as a quick, economical 
and reliable means to assay the activity of other inflammatory stimuli resulting in TLR-dependent 
NF-κB activation.
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Background
The immune system has evolved to recognize not only pathogenic stimuli such as bacterial 
components and viral nucleic acids, but also endogenous danger signals including proteins 
secreted from necrotic cells or expressed upon tissue damage. Both types of stimuli are 
sensed by pattern recognition receptors, initiating signalling cascades that trigger 
inflammatory responses. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB) is a transcription factor essential for the activation of the immune response to infection 
and tissue damage. NF-κB has an important role in the expression of a wide range of 
inflammatory mediators following pattern recognition receptor activation, including 
cytokines (such as tumour necrosis factor α [TNFα], interleukin-6 and interleukin-1), 
chemokines (e.g., interleukin-8 or CXCL1), proteases, growth factors and MHC-related 
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molecules, among others. To assess the activation of this pathway downstream of TLR4, we 
used the commercially available cell line THP1-Blue™ NF-κB (Invivogen). These cells are 
stably transfected with a construct containing a secreted embryonic alkaline phosphatase 
(SEAP) gene induced by the NF-κB transcription factor. The construct contains an 
interferon-β minimal promoter fused to five copies of the NF-κB consensus transcriptional 
response element and three copies of the c-Rel binding site, which drives the expression of 
the reporter gene. After cell stimulation with pathogenic or endogenous stimuli, NF-κB 
activation leads to the secretion of SEAP, which is then quantified using the colorimetric 
reagent QUANTI-Blue™. This is a quick and reliable method to assess activation of NF-κB 
downstream of toll-like receptors, as the amount of SEAP in the media correlates with the 
triggering of this signalling pathway. However, this is an engineered cell line that does not 
express a full complement of inflammatory effector molecules (see Note 5), and so whilst 
useful in screening for NF-κB activation, data should always be confirmed in additional 
experimental systems, for example in primary macrophages, or in vivo.
Materials and Reagents
1. Pipette tips
20 µl (StarLabs, TipOne®, catalog number: S1110-3800)
200 µl (StarLabs, TipOne®, catalog number: S1111-0806)
1,000 µl (StarLabs, TipOne®, catalog number: S1111-6801)
2. Corning 15 ml PP centrifuge sterile tubes (Corning, catalog number: 430791)
3. Cell culture flask 75 cm2 (VWR, catalog number: 734-0012)
4. 96 well plate flat-bottom (VWR, catalog number: 734-0023)
5. THP1-Blue™ NF-κB cells (InvivoGen, catalog number: thp-nfkb)
6. Positive control: LPS from E. coli, Serotype EH100 (Ra) (TLRgrade™) (Enzo 
life sciences, catalog number: ALX-581-010-L002)
7. Test inflammatory stimulus: for example recombinant tenascin-C protein or the 
fibrinogen like globe domain (FBG) of tenascin-C protein (synthesized as 
described in Midwood et al., 2009)
8. Roswell Park Memorial Institute (RPMI) 1640 with L-glutamine (Lonza, catalog 
number: BE12-702F)
9. Fetal bovine serum (FBS), Qualified, heat inactivated (Thermo Fisher Scientific, 
Gibco™, catalog number: 10500064)
10. Penicillin/streptomycin (Thermo Fisher Scientific, Gibco™, catalog number: 
15140122)
11. Normocin™ (InvivoGen, catalog number: ant-nr-1)
12. Blasticidin HCl (Thermo Fisher Scientific, Gibco™, catalog number: R21001)
13. QUANTI-Blue™ (InvivoGen, catalog number: rep-qb1)
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14. ThP1 media without blasticidin (see Recipes)
15. ThP1 media with blasticidin (see Recipes)
16. QUANTI-Blue™ solution (see Recipes)
Equipment
1. P20, P200 and P1000 pipettes
2. 37 °C water bath
3. Hemocytometer
4. CO2 incubator
5. FluoStar Omega plate reader
6. Centrifuge (Thermo Fisher Scientific, model: Heraeus™ MAgefuge™ 16)
7. Rotor (Thermo Fisher Scientific, Thermo Scientific™, model: TX-400 4 x 400 
mL Swinging Bucket Rotor, catalog number: 75003629)
Software
1. Graph Pad Prism
Procedure
A. Cell culture conditions
1. Thaw a vial containing 3-7 x 106 THP1-Blue™ NF-κB cells in a 37 °C 
water bath.
2. Transfer cells to a 15 ml sterile tube containing 10 ml of pre-warmed 
ThP1 NF-κB medium without blasticidin (see Recipes). Centrifuge tube 
at 320 x g for 5 min.
3. Remove supernatant and resuspend cells in 10 ml of ThP1 NF-κB 
medium without blasticidin. Count the cells using a hemocytometer.
4. Transfers 1 x 106 cells in 10 ml of ThP1 NF-κB medium without 
blasticidin to a 75 cm2 cell culture flask and place the culture at 37 °C 
in 5% CO2.
5. The cells grow in suspension. To passage the cells, transfer cells to a 
sterile 15 ml tube and measure cell concentration using a 
hemocytometer. Centrifuge tube at 320 x g for 5 min at room 
temperature, remove cell supernatant and resuspend cells in fresh 
media. Passage the cells every 3 days and do not let the cell 
concentration in the flask exceed 2 x 106 cells/ml.
6. For the first two passages, cells should be cultured in medium without 
blasticidin to allow recovery from freezing. After the second passage, 
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culture the cells in ThP1 NF-κB medium with blasticidin (see Recipes) 
to maintain selection pressure.
B. Cell stimulation
1. Transfer cells to a 15 ml sterile tube. Centrifuge cells at 320 x g for 5 
min. Remove supernatant and resuspend cells in new ThP1 NF-κB 
medium with blasticidin.
2. Plate 1 x 105 cells per well in a flat-bottom 96 well plate in a final 
volume of 100 µl.
3. Immediately after plating, stimulate cells by adding LPS or 
recombinant protein (e.g., FBG) diluted in 100 µl of media in duplicate 
or triplicate wells. The final volume in each well is 200 µl.
4. Incubate the cells for 24 h at 37 °C in 5% CO2 (see Note 3).
5. To measure NF-κB-induced secreted alkaline phosphatase, collect cell 
supernatant.
6. At this stage cells can be taken for assessment of viability for example 
by MTT assay.
C. Measurement of NF-κB activation
1. Warm QUANTI-Blue™ solution (see Recipes) at 37 °C for 10 min.
2. Add 180 µl of QUANTI-Blue™ per well to a flat-bottom 96 well plate.
3. Add 20 µl of THP1-Blue™ cell supernatant to each well.
4. Incubate the plate at 37 °C for 2 h. The media will change color from 
pink to blue in the presence of secreted embryonic alkaline phosphatase 
(Figure 1).
5. Determine SEAP levels by reading the optical density (OD) at 620 nm 
using a spectrophotometer plate reader.
Data analysis
For each stimulus, plot the mean of OD values ± standard error of the mean (SEM), in the 
case of multiple independent experiments (Figure 2), or the mean of OD values ± standard 
deviation (SD), in the case of single experiments. The data can also be represented as fold 
change difference compared to non-stimulated cells. Perform statistical analysis using Graph 
Pad Prism or other software.
Notes
1. QUANTI-Blue™ signal can be detected between 15 min to 24 h after adding cell 
supernatant. Determine the optimal time point for measuring QUANTI-Blue™ 
signal to be able to compare between independent experiments.
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2. THP1-Blue™ NF-κB cells respond robustly to TLR1/2, TLR2/6, TLR4, TLR5, 
TLR8, NOD1 and NOD2 agonists. However, poor responses have been observed 
with TLR3, TLR7 and TLR9 ligands.
3. Robust SEAP signal can be detected from 8 h after cell stimulation with TLR4 
ligands (Figure 3). Nevertheless, it is recommended to titrate the stimulus of 
interest to determine the optimal dose and time point after stimulation to assess 
NF-κB activation.
4. THP1-Blue™ NF-κB cells should not be used after the 12th passage (Figure 4). 
According to the manufacturer (Invivogen), these cells undertake genotypic 
changes that result in reduced responsiveness over time under normal culture 
conditions. It is important to prepare frozen stocks at early passages.
5. THP1-Blue™ NF-κB cells cannot be used to assess cytokine protein expression. 
No cytokines can be reliably detected in the supernatant of these cells after 
activation with LPS (Figure 5).
6. When testing the inflammatory activity of recombinant proteins, the LPS content 
of preparations should be < 10 pg/ml. Additional controls that should be included 
are 1) incubation of the recombinant protein with polymyxin B, an antibiotic that 
inhibits pathogenic activation of TLR4, but which doesn’t affect the recombinant 
protein activity; and 2) boiling the samples, which doesn’t affect LPS activity, 
but denatures the protein, destroying its pro-inflammatory activity (Figure 6).
Recipes
1. ThP1 media without blasticidin
RPMI 1640
10% FBS
1% penicillin/streptomycin
100 µg/ml Normocin™
2. ThP1 media with blasticidin
RPMI 1640
10% FBS
1% penicillin/streptomycin
10 µg/ml blasticidin
100 µg/ml Normocin™
3. QUANTI-Blue™ solution
One pouch of QUANTI-Blue™
100 ml of endotoxin-free water
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Pour the content of one pouch of QUANTI-Blue™ in a sterile flask with 100 ml 
of endotoxin-free water. Incubate QUANTI-Blue™ solution at 37 °C for 30 min 
and swirl gently every 10 min to dissolve the powder. QUANTI-Blue™ solution 
is stable for 2 weeks at 2-8 °C, or two month at - 20 °C. Keep reconstituted 
QUANTI-Blue™ away from light
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Figure 1. Detection of secreted embryonic alkaline phosphatase using QUANTI-Blue™.
Activation of THP1-Blue™ NF-κB cells with decreasing doses of LPS plus negative control 
(NC) performed in duplicates. In the presence of SEAP the QUANTI-Blue™ media changes 
color from pink to blue. The blue color intensity correlates with NF-κB activation at 
different doses.
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Figure 2. NF-κB activation by LPS or the FBG domain of tenascin-C (FBG-C) in THP1-Blue™ 
NF-κB cells.
Cells were stimulated with different doses of LPS or FBG-C or left unstimulated (-) and 
after 24 h NF-κB activation was measured using QUANTI-Blue™. Data shown as mean ± 
SEM, N = 3 independent experiments. One-way ANOVA vs. non-stimulated with Dunnett’s 
post hoc test, *P < 0.05, **P < 0.01, ***P < 0.001. Statistical analysis was performed using 
Graph Pad Prism.
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Figure 3. Time course of NF-κB activation in THP1-Blue™ NF-κB cells.
Cells were stimulated with 1 ng/ml of LPS or 1 μM FBG-C and NF-κB activation was 
measured using QUANTI-Blue™ at different time points. Data shown as mean ± SEM, N = 
3 independent experiments. One-way ANOVA vs. time 0 h with Dunnett’s post hoc test, *P 
< 0.05, **P < 0.01, ***P < 0.001.
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Figure 4. Measurement of NF-κB activation in THP1-Blue™ NF-κB cells at different passages.
Cells from different passages were stimulated with 0.5 ng/ml of LPS or left unstimulated (-) 
and NF-κB activation was measured after 24 h using QUANTI-Blue™. Data shown as mean 
± SEM, N = 3. Paired t-test vs. non-stimulated, *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 5. THP1-Blue™ NF-κB cells do not express cytokines.
Cells were stimulated with different doses of LPS or left unstimulated (-) and NF-κB 
activation was measured after 24 h using QUANTI-Blue™; or cytokine synthesis (IL-8, 
TNF and IL-6) was measured by ELISA. Data shown as mean ± SD, N = 2 independent 
experiments.
Zuliani-Alvarez et al. Page 11
Bio Protoc. Author manuscript; available in PMC 2017 April 10.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 6. Effect of polymyxin B (PMB) and boiling on LPS and FBG-C activity in THP1-Blue™ 
NF-κB cells.
Cells were left unstimulated (-) or stimulated with LPS or FBG-C pre-incubated with PMB 
for 30 min or boiled for 15 min. NF-κB activation was measured using QUANTI-Blue™. 
Data shown as mean ± SEM, N = 4 independent experiments. Paired t-test vs. non-treated, 
***P < 0.001.
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